During the last session, Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)’s traded shares were 3.77 million, with the beta value of the company hitting 0.90. At the end of the trading day, the stock’s price was $11.35, reflecting an intraday loss of -11.81% or -$1.52. The 52-week high for the ARWR share is $30.41, that puts it down -167.93 from that peak though still a striking 15.68% gain since the share price plummeted to a 52-week low of $9.57. The company’s market capitalization is $1.56B, and the average intraday trading volume over the past 10 days was 2.66 million shares, and the average trade volume was 2.05 million shares over the past three months.
Arrowhead Pharmaceuticals Inc (ARWR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.57. ARWR has a Sell rating from 0 analyst(s) out of 9 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.46.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) trade information
Arrowhead Pharmaceuticals Inc (ARWR) registered a -11.81% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -11.81% in intraday trading to $11.35, hitting a weekly high. The stock’s 5-day price performance is -3.81%, and it has moved by -24.81% in 30 days. Based on these gigs, the overall price performance for the year is -52.73%. The short interest in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is 11.98 million shares and it means that shorts have 7.13 day(s) to cover.
The consensus price target of analysts on Wall Street is $26.98, which implies an increase of 57.93% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $24 and $29.97 respectively. As a result, ARWR is trading at a discount of -164.05% off the target high and -111.45% off the low.
Arrowhead Pharmaceuticals Inc (ARWR) estimates and forecasts
In the rating firms’ projections, revenue will increase 8,932.46% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 116.27M as predicted by 11 analyst(s). Meanwhile, a consensus of 11 analyst(s) estimates revenue growth to 51.27M by the end of current fiscal year.
While earnings are projected to return 41.08% in 2025, the next five years will return 11.11% per annum.
ARWR Dividends
Arrowhead Pharmaceuticals Inc is due to release its next quarterly earnings on 2025-Feb-09. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)’s Major holders
Arrowhead Pharmaceuticals Inc insiders own 13.09% of total outstanding shares while institutional holders control 74.63%, with the float percentage being 85.87%. BLACKROCK INC. is the largest shareholder of the company, while 364.0 institutions own stock in it. As of 2024-06-30, the company held over 15.68 million shares (or 12.6275% of all shares), a total value of $407.61 million in shares.
The next largest institutional holding, with 12.21 million shares, is of VANGUARD GROUP INC’s that is approximately 9.9072% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $317.44 million.
